Xponance Inc. Has $395,000 Stock Position in Amedisys, Inc. (NASDAQ:AMED)

Xponance Inc. raised its holdings in Amedisys, Inc. (NASDAQ:AMED) by 3.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,349 shares of the health services provider’s stock after buying an additional 148 shares during the quarter. Xponance Inc.’s holdings in Amedisys were worth $395,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Blue Trust Inc. increased its stake in shares of Amedisys by 55.1% in the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock valued at $34,000 after acquiring an additional 124 shares in the last quarter. HBW Advisory Services LLC bought a new stake in Amedisys in the fourth quarter valued at $38,000. Versant Capital Management Inc raised its holdings in shares of Amedisys by 68.5% during the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock valued at $41,000 after purchasing an additional 183 shares during the period. Vestcor Inc bought a new position in shares of Amedisys during the 4th quarter worth about $73,000. Finally, Venturi Wealth Management LLC grew its stake in shares of Amedisys by 397.4% in the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider’s stock valued at $89,000 after buying an additional 779 shares during the period. 94.36% of the stock is currently owned by institutional investors.

Amedisys Stock Up 0.1 %

Shares of NASDAQ AMED opened at $92.43 on Thursday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The company has a 50-day moving average price of $92.24 and a 200-day moving average price of $92.50. The stock has a market capitalization of $3.03 billion, a P/E ratio of 36.68, a P/E/G ratio of 1.78 and a beta of 0.76. Amedisys, Inc. has a 1 year low of $82.15 and a 1 year high of $98.95.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Wednesday, February 26th. The health services provider reported $0.96 EPS for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The company had revenue of $598.05 million for the quarter, compared to the consensus estimate of $602.38 million. On average, equities research analysts forecast that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Stephens reaffirmed an “equal weight” rating and set a $101.00 price target on shares of Amedisys in a research note on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $101.00.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.